[PRTO] Proteon Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.95 Change: -0.1 (-4.88%)
Ext. hours: Change: 0 (0%)

chart PRTO

Refresh chart

Strongest Trends Summary For PRTO

PRTO is in the medium-term up 59% above S&P in 1 month. In the long-term down -79% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Proteon Therapeutics Inc develops pharmaceuticals to treat renal and vascular diseases. The company is developing PRT-201, a recombinant human elastase, which is in Phase III clinical trials for the treatment of radiocephalic arteriovenous fistula; and has completed a Phase I/II trial for the treatment of patients undergoing surgical placement of an arteriovenous graft. The company was founded in 2001 and is based in Waltham, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-3.12% ROE-3.23% ROI
Current Ratio30.65 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-55.18 M Cash From Operating Activities-3.87 M Gross Profit
Net Profit-4.58 M Operating Profit-4.62 M Total Assets80.93 M Total Current Assets80.73 M
Total Current Liabilities2.63 M Total Debt Total Liabilities2.63 M Total Revenue
Technical Data
High 52 week2.85 Low 52 week1.53 Last close2.57 Last change4.05%
RSI79.25 Average true range0.16 Beta0.6 Volume264.56 K
Simple moving average 20 days14.15% Simple moving average 50 days32.58% Simple moving average 200 days19.34%
Performance Data
Performance Week-1.15% Performance Month39.67% Performance Quart55.76% Performance Half4.9%
Performance Year9.36% Performance Year-to-date13.22% Volatility daily5.05% Volatility weekly11.3%
Volatility monthly23.16% Volatility yearly80.22% Relative Volume121.33% Average Volume42.96 K
New High New Low-0%

News

2018-12-20 10:49:59 | Does The Proteon Therapeutics, Inc. NASDAQ:PRTO Share Price Fall With The Market?

2018-11-16 07:35:00 | New Research Coverage Highlights Yum! Brands, TELUS, Unifi, Proteon Therapeutics, Sabine Royalty Trust, and Algonquin Power & Utilities — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-08 07:45:00 | Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th

2018-11-07 10:03:42 | Proteon Therapeutics: 3Q Earnings Snapshot

2018-11-07 08:00:00 | Proteon Therapeutics Announces Third Quarter 2018 Financial Results

2018-09-17 15:10:45 | Is Proteon Therapeutics Inc NASDAQ:PRTO A Strong Healthcare Bet?

2018-08-07 08:11:39 | Proteon Therapeutics: 2Q Earnings Snapshot

2018-08-07 08:00:00 | Proteon Therapeutics Announces Second Quarter 2018 Financial Results

2018-06-14 08:00:00 | Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

2018-05-15 19:07:10 | Proteon Therapeutics Inc’s NASDAQ:PRTO Earnings Dropped -27.47%, How Did It Fare Against The Industry?

2018-05-10 07:05:00 | Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient

2018-05-09 08:24:32 | Proteon Therapeutics: 1Q Earnings Snapshot

2018-05-09 08:10:00 | Proteon Therapeutics Announces First Quarter 2018 Financial Results

2018-05-08 07:00:00 | Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

2018-03-14 08:06:23 | Proteon Therapeutics Inc NASDAQ:PRTO: Are Analysts Optimistic?

2018-03-14 08:00:00 | Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

2018-03-06 16:45:00 | Proteon Therapeutics to Present at Two Upcoming Investor Conferences

2018-03-05 17:00:00 | Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase

2017-11-08 08:00:00 | Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th

2017-11-07 08:29:48 | Proteon Therapeutics reports 3Q loss

2017-11-07 08:00:00 | Proteon Therapeutics Announces Third Quarter 2017 Financial Results

2017-09-05 07:45:00 | Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017

2017-08-07 19:50:41 | Proteon Therapeutics reports 2Q loss

2017-08-07 17:00:00 | Proteon Therapeutics Announces Second Quarter 2017 Financial Results

2017-08-02 19:30:00 | Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing

2017-06-22 09:32:07 | Proteon Therapeutics Announces $22.0 Million Private Placement

2017-06-15 08:00:00 | Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

2017-05-10 08:08:28 | Proteon Therapeutics reports 1Q loss

2017-05-10 08:00:00 | Proteon Therapeutics Announces First Quarter 2017 Financial Results

2017-05-10 07:30:00 | Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase

2017-05-02 16:40:00 | Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial

2017-05-01 08:00:00 | Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th

2017-04-05 20:01:00 | Lifshitz & Miller LLP Announces Investigation of BRF S.A., Innoviva, Inc., Panera Bread Company, PRA Group, Inc., Proteon Therapeutics, Inc., tronc, Inc. and Vuzix Corporation

2017-03-23 16:41:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc.

2017-03-22 06:04:15 | PROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

2017-03-17 09:20:08 | Proteon CEO: New trial could be a path to market

2017-03-17 07:55:00 | Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd

2017-03-16 08:01:27 | Proteon Therapeutics reports 4Q loss

2017-03-16 07:16:03 | PROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,

2017-03-16 07:15:00 | Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial

2017-03-16 07:04:01 | PROTEON THERAPEUTICS INC Files SEC form 10-K, Annual Report

2017-02-06 17:00:00 | Proteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting

2017-01-05 13:37:00 | These 5 Stocks Under $10 Could Make You a Lot of Money

2016-12-16 20:51:23 | How ProQR Therapeutics NV PRQR Stacks Up Against Its Peers

2016-12-14 13:30:08 | Failure in late clinical trial pummels Proteon Therapeutics stock

2016-12-14 13:15:06 | Failure in late clinical trial pummels Proteon Therapeutics stock

2016-12-14 07:39:12 | Proteon Slips to 52-Week Low on Kidney Disease Study Data

2016-12-13 11:25:09 | Proteon Therapeutics Craters on Missed Late-Stage Results

2016-12-13 09:34:38 | Waltham biotech's shares tank after kidney disease drug flunks trial

2016-12-13 07:54:44 | Proteon Therapeutics' stock plummets after failed trial of kidney disease treatment